Genco Shipping & Trading (GNK) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.28 per share a year ago.
Genco Shipping (GNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GNK rides on fleet expansion, strong liquidity and shareholder payouts, fueling a 65% surge and bullish outlook as earnings estimates climb.
Here is how Genco Shipping & Trading (GNK) and International Seaways (INSW) have performed compared to their sector so far this year.
Shares of Genco Shipping and Trading Limited (NYSE: GNK - Get Free Report) have earned an average recommendation of "Buy" from the six research firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and three have issued a
Here is how Genco Shipping & Trading (GNK) and International Seaways (INSW) have performed compared to their sector so far this year.
Genco Shipping (GNK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Genco Shipping & Trading Limited (GNK) Q4 2025 Earnings Call Transcript
Genco Shipping & Trading (GNK) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.29 per share a year ago.
Following a careful analysis of the Zacks Transportation Shipping industry, we advise buying stocks like ZIM, GNK and SHIP.
The nominations come days after Genco rejected Diana's offer to acquire the company via an all-cash deal. Diana has a roughly 14.8% stake in Genco.
Genco Shipping (GNK) received a $20.60/share cash buyout proposal from Diana Shipping (DSX), validating the bull thesis of asset undervaluation. DSX seeks GNK's strong balance sheet and cash flows to offset its own leverage, but the offer is near or below GNK's NAV and lacks a control premium. GNK's poison pill and robust financials empower the board to demand a higher bid or shop for alternative offers, with fair value estimated at $24–25/share.